GlaxoSmithKline (GSK) and Innoviva (INVA) recently published promising data about the Salford Lung Study (SLS) in chronic obstructive pulmonary disease (COPD). The clinical trial demonstrated that Relvar Ellipta (fluticasone furoate and vilanterol) could reduce exacerbations compared to usual care, for people with COPD. Usual care involved long-acting muscarinic antagonists (LAMA), long-acting beta2-agonists…
Therabron Therapeutics, a biotech company developing a novel class of drugs based on the naturally occurring secretoglobin proteins, announced a new research program to develop a series of new isoforms of their lead candidate, the recombinant human CC10 protein. Therabron plans to provide treatment for a range of orphan and more commonplace…
Boehringer Ingelheim Pharmaceuticals, Inc., recently released data showing that Stiolto Respimat (inhalation spray) improved lung function over a range of measures in patients with chronic obstructive pulmonary disease (COPD), when compared to a European formulation of a long-acting beta agonist (salmeterol) and an inhaled corticosteroid (fluticasone propionate). Stiolto Respimat was approved…
Get regular updates to your inbox.